Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30502812 | 1.00 | ALDH1A1 (0.54) | ALDH1A1LMNAMEN1KMT2AHTT | |
| SCHEMBL26890594 | 0.92 | ALDH1A1 (0.54) | ALDH1A1LMNAMEN1KMT2AHTT | |
| SCHEMBL25433999 | 0.91 | ALDH1A1 (0.53) | ALDH1A1LMNAMEN1KMT2AHTT | |
| SCHEMBL25434818 | 0.88 | ALDH1A1 (0.50) | ALDH1A1LMNAMEN1KMT2AHTT | |
| SCHEMBL30502815 | 0.86 | PKM (0.47) | ALDH1A1LMNAMEN1KMT2AHTT | |
| SCHEMBL2520783 | 0.86 | PKM (0.47) | ALDH1A1LMNAMEN1KMT2AHTT | |
| SCHEMBL31217219 | 0.86 | ALDH1A1 (0.47) | ALDH1A1LMNAMEN1KMT2AHTT | |
| SCHEMBL30502819 | 0.86 | PKM (0.47) | ALDH1A1LMNAMEN1KMT2AHTT | |
| SCHEMBL25433441 | 0.84 | ALDH1A1 (0.54) | ALDH1A1LMNAMEN1KMT2AHTT | |
| SCHEMBL25434397 | 0.83 | ALDH1A1 (0.56) | ALDH1A1LMNAMEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624052-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260008789-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12421254-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250243222-A1 | PYRIMIDINE BASED MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-20250051365-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| US-20250042921-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2025-02-06 | — | — | US | disclosed |
| US-12145947-B2 | Pyrimidine based modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240199650-A1 | PYRIMIDINE BASED MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2024-06-20 | — | — | US | disclosed |
| WO-2024115890-A1 | COMPOUNDS | REDX PHARMA PLC (GB) | 2024-06-06 | — | — | WO | disclosed |
| US-11912723-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20150175614-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20150175614-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2015-06-25 | — | — | US | disclosed |
| US-8946223-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946223-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946223-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| WO-2011130163-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011130163-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| US-20110251184-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251184-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251184-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12145947-B2 | Pyrimidine based modulators and uses thereof | KRAS, NRAS, DPYD | ALDH1A1 1020/4885LMNA 3966/4885MEN1 2585/4885 |
| US-20250243222-A1 | PYRIMIDINE BASED MODULATORS AND USES THEREOF | KRAS, NRAS, DPYD | ALDH1A1 1020/4885LMNA 3966/4885MEN1 2585/4885 |
| US-20150175614-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, H1-3 | ALDH1A1 828/4885LMNA 538/4885MEN1 1840/4885 |
| US-20110251184-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, H1-3 | ALDH1A1 828/4885LMNA 538/4885MEN1 1840/4885 |
| US-20260008789-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | ALDH1A1 3020/4885LMNA 3054/4885MEN1 646/4885 |
| US-12421254-B2 | KRAS modulators and uses thereof | KRAS, NRAS, HRAS | ALDH1A1 3153/4885LMNA 3135/4885MEN1 449/4885 |
| US-20240199650-A1 | PYRIMIDINE BASED MODULATORS AND USES THEREOF | KRAS, NRAS, DPYD | ALDH1A1 1020/4885LMNA 3966/4885MEN1 2585/4885 |
| US-20250042921-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | ALDH1A1 3974/4885LMNA 3992/4885MEN1 667/4885 |
| US-20250051365-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | ALDH1A1 3319/4885LMNA 2706/4885MEN1 458/4885 |
| US-12624052-B2 | KRAS modulators and uses thereof | KRAS, NRAS, HRAS | ALDH1A1 3044/4885LMNA 3905/4885MEN1 1379/4885 |
| US-11912723-B2 | KRAS modulators and uses thereof | KRAS, NRAS, HRAS | ALDH1A1 3733/4885LMNA 4214/4885MEN1 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.